Dasatinib Reference

Reference summary

Off-label senolytic interest centers on the Justice 2019 EBioMedicine first-in-human pilot in idiopathic pulmonary fibrosis (n=14, open-label, 9 days of D+Q intermittent dosing reported improvements in physical function measures) and the Hickson 2019 EBioMedicine pilot in diabetic kidney disease (n=9, reduced senescent-cell burden in adipose tissue and skin biopsies). Both are small, early-phase, surrogate-endpoint trials. The on-label CML/ALL evidence base is large and mature but is a different clinical use case.

Regulatory and posture

Categories

Longevity

Aliases

Sprycel, BMS-354825, Tyrosine kinase inhibitor (small molecule, not a peptide), Component of the D+Q senolytic combination

Evidence posture

human - Off-label senolytic use rests on two small open-label pilots; no Phase 3 outcome trial exists. The on-label CML/ALL profile includes a substantial adverse-event burden (myelosuppression, pleural effusion, pulmonary hypertension) that is part of the oncology prescribing record.

Regulatory status

FDA-approved as Sprycel (2006) as a tyrosine kinase inhibitor for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Prescription oncology drug. Off-label use as a senolytic in combination with quercetin (the D+Q combination) is investigational and is not on the FDA label.

Content review status

label verified